We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Memory Pharmaceuticals Corp (MM) | NASDAQ:MEMY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.606 | 0 | 01:00:00 |
Transaction
Valuation*
|
Amount
of Filing Fee**
|
$50,435,251.01
|
$1,982.11
|
*
|
Estimated for purposes of
calculating the filing fee only. This amount assumes the purchase of all
82,243,050 shares of common stock of Memory Pharmaceuticals Corp.
outstanding as of November 20, 2008 and options outstanding as of November
20, 2008 with respect to
1,708,030
shares of common stock of Memory
Pharmaceuticals Corp.
|
**
|
The amount of the filing fee is
calculated in accordance with Rule 0-11 of the Securities Exchange Act of
1934, as amended, by multiplying the transaction valuation by
0.00003930.
|
R
|
Check box if any part of the fee
is offset as provided by Rule 0-11(a)(2) and identify the filing with
which the offsetting fee was previously paid. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of
its filing.
|
Amount
Previously Paid:
|
$1,192.11
|
Filing
Party:
|
Hoffmann-La
Roche Inc.
|
|
Form
or Registration No.:
|
SC
TO-T
|
Date
Filed:
|
December
3, 2008
|
£
|
Check the box if the filing
relates solely to preliminary communications made before the commencement
of a tender offer.
|
R
|
third-party tender offer subject
to Rule 14d-1.
|
£
|
issuer tender offer subject to
Rule 13e-4.
|
£
|
going-private transaction subject
to Rule 13e-3.
|
R
|
amendment to Schedule 13D under
Rule 13d-2.
|
(a)(5)(iii)
|
Press
Release issued by Roche Holding Ltd, dated January 2,
2009.
|
900
NORTH POINT ACQUISITION CORPORATION
|
||||
By:
|
/s/ | Frederick C. Kentz III | ||
Name: |
Frederick
C. Kentz III
|
|||
Title: |
President
|
|||
HOFFMANN-LA
ROCHE INC.
|
||||
By:
|
/s/ | Frederick C. Kentz III | ||
Name: |
Frederick
C. Kentz III
|
|||
Title: |
Vice
President
|
Exhibit
No.
|
Description
|
(a)(1)(i)
|
Offer
to Purchase dated
December
3
, 2008.*
|
(a)(1)(ii)
|
Letter
of Transmittal (including Guidelines for Certification of Taxpayer
Identification Number on Substitute Form W-9).*
|
(a)(1)(iii)
|
Notice
of Guaranteed Delivery.*
|
(a)(1)(iv)
|
Letter
to Brokers, Dealers, Commercial Banks, Trust Companies and Other
Nominees.*
|
(a)(1)(v)
|
Letter
to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies
and Other Nominees.*
|
(a)(1)(vi)
|
Summary
Advertisement dated
December
3
, 2008.*
|
(a)(5)(i)
|
Press
Release issued by Roche Holding Ltd, dated November 25,
2008.*
|
(a)(5)(ii)
|
Complaint
filed by Marc Cappello and Jerry W. Burk on December 9, 2008 in the
Superior Court of New Jersey, Chancery Division, Bergen County (Case No.
C-522-08).*
|
(a)(5)(iii)
|
Press
Release issued by Roche Holding Ltd, dated January 2,
2009.
|
(b)
|
Not
applicable.
|
(c)
|
Not
applicable.
|
(d)(1)
|
Agreement
and Plan of Merger, dated as of November 25, 2008, among Memory
Pharmaceuticals Corp., Hoffmann-La Roche Inc. and 900 North Point
Acquisition Corporation (incorporated by reference to the Form 8-K filed
by Memory Pharmaceuticals Corp. on November 25, 2008).
|
(d)(2)
|
Tender
and Support Agreement, dated as of November 25, 2008, among Hoffmann-La
Roche Inc. and certain stockholders listed on the signature page thereto
(incorporated by reference to the Schedule 14D-9 filed by Memory
Pharmaceuticals Corp. on December 3, 2008).
|
(d)(3)
|
Confidentiality
Agreement, dated October 29, 2008, between F. Hoffmann-La Roche Ltd and
Memory Pharmaceuticals Corp. (incorporated by reference to the Schedule
14D-9 filed by Memory Pharmaceuticals Corp. on December 3,
2008).
|
(e)
|
Not
applicable.
|
(f)
|
Not
applicable.
|
(g)
|
Not
applicable.
|
(h)
|
Not
applicable.
|
1 Year Memory Pharmaceuticals Corp (MM) Chart |
1 Month Memory Pharmaceuticals Corp (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions